Moleculin Enters Agreement with Seidman Cancer Center to Conduct Leukemia Clinical Trials

by in

Moleculin today announced that it has partnered with The University Hospitals Cleveland Medical Center to participate in its U.S. Phase I/II clinical trial of Annamycin.